Lung Monitoring Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Lung Monitoring Devices Market is projected to expand from USD 4.16 Billion in 2025 to USD 6.11 Billion by 2031, achieving a compound annual growth rate of 6.62%. Lung monitoring devices are specialized diagnostic and therapeutic tools designed to evaluate critical respiratory parameters, such as gas exchange, lung capacity, and airflow obstruction, ensuring effective management of pulmonary conditions. The market's growth is primarily driven by the increasing prevalence of chronic respiratory disorders and a growing geriatric population that is highly susceptible to lung ailments. For instance, the International Pharmaceutical Federation reported in 2024 that 391 million individuals globally were living with chronic obstructive pulmonary disease, creating an urgent need for accurate assessment tools to prevent long-term complications and driving their adoption across healthcare facilities.

However, the market faces a significant obstacle in the form of high acquisition costs for advanced monitoring systems, particularly when combined with insufficient reimbursement frameworks in emerging economies. These financial barriers restrict access to modern respiratory care technologies for healthcare providers in low-income regions, effectively limiting market penetration. Despite the growing clinical necessity for comprehensive respiratory health management, these economic constraints prevent the broader expansion of the market and hinder the availability of essential diagnostic tools in areas where they are often needed most.

Market Drivers

Technological advancements in smart and wearable monitoring devices are revolutionizing the Global Lung Monitoring Devices Market by significantly improving diagnostic precision and patient convenience. The incorporation of artificial intelligence and contactless sensors enables the continuous evaluation of respiratory functions without relying on cumbersome hardware, aligning with the industry's shift toward non-invasive, accessible solutions. For example, Mindset Medical announced in June 2025 that it received FDA clearance for a software-only application capable of measuring respiratory rates using standard smartphone cameras. This development illustrates how digital health tools are lowering barriers to entry and fostering the widespread adoption of respiratory tracking technologies across a diverse range of patient demographics.

Simultaneously, the transition toward remote patient monitoring and home healthcare is creating substantial market opportunities as healthcare systems aim to decrease hospital admissions. This trend is fueled by the necessity to manage chronic conditions outside traditional clinical settings, a need intensified by worsening environmental factors. The American Lung Association noted in 2025 that approximately 156 million people in the U.S. lived in areas with unhealthy air pollution levels, sustaining the demand for home-based management solutions. Consequently, major market players are experiencing robust growth from these decentralized models; ResMed reported a 10% revenue increase to $1.3 billion in its July 2025 quarterly results, highlighting the commercial viability and rising uptake of remote respiratory care technologies.

Market Challenges

The expansion of the Global Lung Monitoring Devices Market is heavily restricted by the high acquisition costs of advanced monitoring systems and inadequate reimbursement structures. Healthcare facilities, particularly those in emerging economies, often face significant capital constraints that prevent investment in modern diagnostic equipment. This barrier is exacerbated when insurers and public health programs provide insufficient coverage for these technologies, making advanced respiratory care financially unfeasible for many providers. As a result, hospitals are frequently forced to delay necessary equipment upgrades, which directly stifles the adoption of precise monitoring tools and limits market penetration in regions where the burden of respiratory disease is often highest.

This lack of financial accessibility not only reduces potential market revenue but also creates inefficiencies in patient care that lead to substantial economic losses. The inability to deploy these devices contributes to missed diagnoses and poor disease management. According to the European Respiratory Society, in 2025, the underdiagnosis and misdiagnosis of chronic respiratory diseases cost the European region an estimated $21 billion annually. This figure underscores how funding gaps and financial constraints impede the widespread integration of monitoring solutions, preventing the market from reaching its full potential while increasing the long-term economic strain on healthcare systems.

Market Trends

The development of multi-parameter cardio-respiratory devices is transforming the market by consolidating various diagnostic functions into compact, clinical-grade tools for holistic health assessment. Manufacturers are increasingly designing devices that simultaneously track cardiovascular and pulmonary metrics, acknowledging the critical relationship between heart and lung function in the management of chronic diseases. This convergence simplifies the patient experience by eliminating the need for multiple disparate gadgets and enhances the quality of data available for remote clinical evaluation. For instance, Withings received FDA clearance in November 2025 for its BeamO device, a 4-in-1 multiscope retailing for $249.95 that combines a digital stethoscope, electrocardiogram, and oximeter into a single handheld unit.

In parallel, the adoption of smart connected inhalers and nebulizers is gaining momentum as the industry shifts priority toward medication adherence and data-driven therapeutic management rather than passive drug delivery. These next-generation systems integrate with digital health ecosystems to bridge the gap between patients and providers, ensuring respiratory treatments are administered correctly and monitored in real-time. This connectivity supports proactive intervention strategies that can prevent disease progression and reduce the burden on acute care facilities. Highlighting this trend, Omron Healthcare announced in October 2025 that cumulative sales of its nebulizers had surpassed 50 million units, demonstrating the massive global scale and growing reach of these respiratory management solutions within connected care networks.

Key Players Profiled in the Lung Monitoring Devices Market

• Baxter International Inc.
• Becton, Dickinson and Company
• ICU Medical Inc.
• Koninklijke Philips N.V.
• Masimo Corporation
• Medtronic PLC
• Nihon Kohden Corporation
• ResMed Inc.
• Teleflex Incorporated.
• Vyaire Medical, Inc.

Report Scope

In this report, the Global Lung Monitoring Devices Market has been segmented into the following categories:

Lung Monitoring Devices Market, by Product Type:

• Spirometers
• Pulse Oximeters
• Capnographs
• Others

Lung Monitoring Devices Market, by End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Lung Monitoring Devices Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Monitoring Devices Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.